IL6R and COVID-19: In this sense, the humanized anti-interleukin-6-receptor (IL-6R) monoclonal antibody (Tocilizumab), a drug used against rheumatoid arthritis (85) that inhibits IL-6 signaling, has been administered experimentally in treatment of COVID-19 (87).